Drug Profile
Research programme: proteolysis targeting chimeric molecules - Boehringer Ingelheim/University of Dundee
Alternative Names: BET PROTAC - Boehringer Ingelheim/University of Dundee; MZ-1; SMARC2 protein degader - Boehringer Ingelheim/University of DundeeLatest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; University of Dundee
- Class
- Mechanism of Action Protease stimulants; Ubiquitin protein ligase complex modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Immunological disorders; Respiration disorders
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Cancer in Germany
- 28 Aug 2020 No recent reports of development identified for research development in Immunological-disorders in Germany
- 28 Aug 2020 No recent reports of development identified for research development in Respiration-disorders in Germany